The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Takeda’s Cx601 Stem Cell Therapy Hits Primary Endpoint in Global PIII
August 3, 2016
- Shionogi to Transfer 21 Off-Patent Products to Kyowa Pharm
August 3, 2016
- Opdivo Hauls in 25.2 Billion Yen in April-June
August 3, 2016
- Nichi-Iko Launches Tender Offer for Sagent
August 3, 2016
- Japan Market Grows in April-June on Hep C Meds, Opdivo: IMS
August 2, 2016
- Gil Feldman Picked as President of Teva API Japan
August 2, 2016
- Halaven Extends Duration of Response in Soft Tissue Sarcoma: Global PIII
August 2, 2016
- Sunovion Submits US NDA for COPD Drug
August 2, 2016
- Positive Changes Seen in Oncology R&D under New Head: Daiichi Sankyo CEO
August 2, 2016
- Kyowa Kirin to Stress Effectiveness of Psoriasis Drug Lumicef in Promotion: President
August 2, 2016
- Takeda to Revamp R&D Organization, Eyes Consolidated Research Sites in Japan, US
August 1, 2016
- Janssen Files HIV Combo Pill in Japan
August 1, 2016
- Otsuka Ups January-June Profit Forecasts
August 1, 2016
- Taiho Seeks Two Add’l Indications for Zosyn
August 1, 2016
- Chugai Hemophilia A Treatment Yields Positive Data in Japan PI/II
July 29, 2016
- Astellas, Cytokinetics Expand Collaboration into ALS
July 29, 2016
- Damage Suit Filed over HPV Vaccines; MSD Says Claims Scientifically Unfounded
July 28, 2016
- Teijin Files Somatuline for Neuroendocrine Tumor in Japan
July 28, 2016
- Ono Seeks Japan OK for Opdivo’s Head and Neck Cancer Indication
July 28, 2016
- Sumitomo Dainippon Trio to Research Method for Pre-RPE Cell Transplant Immune Reaction Testing
July 27, 2016
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…